

Regd.Office: Dare House, 234,N.S.C. Bose Road, Parrys Corner, Chennai 600 001, India.

Tel: 91.44.25306789 Fax: 91.44.25341609 / 25340858

ÇIN: L24211TN1975PLC006989 Website: www.eidparry.com

May 17, 2022

BSE Limited

1st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001.

Scrip Code: 500125

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

EIDPARRY

Dear Sir/ Madam,

Subject: Presentation to analysts on Audited Financial Results (Consolidated and Standalone) for the guarter / year ended March 31, 2022

The presentation on the Audited Financial Results (Consolidated and Standalone) for the quarter / year ended March 31, 2022, for the Analyst / Investors Call to be held tomorrow (May 18, 2022) is enclosed.

We request you to kindly take the above information on record.

Thanking you

Yours faithfully

For E.I.D. - PARRY (INDIA) LIMITED

Biswa Mohan Rath Company Secretary

Encl: As attached









E.I.D. - PARRY (INDIA) LIMITED

INVESTOR PRESENTATION

FY'22



5 COMPANY INFORMATION

8 INDUSTRY ANALYSIS

13 SUGAR STRATEGY

27

31

23 E.I.D. STANDALONE PERFORMANCE

NUTRACEUITCALS PERFORMANCE

REFINERY PERFORMANCE






Safe Harbour



Certain statements made in this document may constitute forward-looking statements. These forward-looking statements are based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable.

However, these forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

EID Parry will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



CORPORATE INFORMATION





About Us

E.I.D. – Parry (India) Limited (EID) is a listed company engaged in the business of Sugar and Nutraceuticals

Headquartered in 'Dare House' a heritage building, in Chennai, India.

Founded in 1788, 'Parry' has been a household name for over 225 years.

Revenue for FY'22 ₹ 2,496 Cr

Market Cap [31 Mar'22] ₹ 8,026 Cr

Part of the INR 417
Billion Murugappa
Group, one of
India's leading
business
conglomerates.

Leading Sugar producer in South with 6 Sugar factories and a standalone distillery in South

Nutraceuticals
division with more
than 3 decades of
expertise in microalgae cultivation. 1st
and only USP
ingredient verified
Spirulina

	Our Capacity				
Location	Sugar [TCD]	Power (MW)	Distillery (KLPD)		
Nellikuppam – TN	7,500	25	75		
Pugalur – TN	4,800	22	-		
Haliyal – KN	12,000	49	50		
Bagalkot – KN	6,000	16	60		
Ramdurg – KN	5,000	13	-		
Sankili – AP	5,000	16	48*		
Sivagangai – TN	-	-	64		
Total	40,300	140	297		

^{*}New capacity addition of 120 KLPD at Sankili is in progress



murugappa

E.I.D. - Parry (India) Limited

Our Many Firsts



1st sugar

to start a

distillery in

manufacturer

India in 1843.

1st Sugar Company in India to manufacture sugar in 1842 &

Earliest sugar manufacturers in the world.



1st sugar manufacturer in India to initiate farmercentric model of business as early as 1845.



1st and amongst the few sugar manufacturers in India with a dedicated R&D wing and cane breeding programme.



Parrys Pure is the only sugar brand to be conferred the 'Super Brand' status in India.



Fully automated distillery plant in Sivagangai started in 2009, 1st of its kind in the country with "Zero emission, effluent and captive power generation capability.




natural beta

carotenoids.

In the Social Nutraceuticals space, E.I.D. Parry is a world Award on 24th leader in micro algae March 2022 technology comprising spirulina and





INDUSTRY ANALYSIS





Global Sugar Scenario Update

Global recovery underway

Global per capita sugar consumption hit during the pandemic year to the levels as that were as far back in 2009. It is poised to recover and grow more than 1.5% pa

Robust Refined sugar demand

is expected to keep trade flows balanced.

Ukraine crisis

EU production will be lower leading to imports of Sugar to EU

Boost to Ethanol

- Higher level of sugar diversion to ethanol is expected in India
- Higher global energy prices are supportive for hydrous ethanol price in Brazil, leading to lower sugar-mix estimates for the center-south

Record Indian production & export

- Indian production overshadows lower output in other countries, bringing 2020-21 supply and demand to a surplus of 1.26 MMT
- Export volumes to be significant in SY 22-23 on the back of record exports in SY 21-22

Lower production in China

Production may not reach 10 MMT in current year for the first time since 2016/17 leading to higher imports of raw sugar

Lower Crop in

Brazil (due to weather) to be compensated by higher production in India & Thailand. EU may turn net importer due to ongoing conflict


Sources: Czarnikow report & S&P Platts





Global Sugar Scenario & Consumption


GLOBAL SUGAR BALANCE AND WORLD PRICE




Source: S&P Global Commodity Insights

- Global per capita sugar consumption is poised to recover from pandemic and is on path to grow more than 1.5% pa
- Higher Indian Production offsets the production shortfall faced by rest of the world.

Per Capita Sugar Consumption



Global Sugar Consumption







Key Policies - GOI

Sugar Year 2019-20	Sugar Year 2020-21	Key Policy	Sugar Year 2021-22
4 MMT	Nil	Buffer Stock Quantity	Nil
31	31	MSP – Rs/Kg of Sugar	31
2750	2850	FRP – Rs/Ton of Cane	2900
Imposed	Imposed	Restriction of domestic sales quantity through Release Order	Imposed
5.9 MMT	6.0 MMT	MAEQ-Export	Not Announced
В	B, Syrup & Grain	OMC Ethanol	B, Syrup & Grain

Notes:

- > In March 2020, Niti Aayog recommended increase in MSP by Rs.2/-Kg. However, this is yet to happen.
- > Transport subsidy withdrawn by Tamil Nadu Government





Indian Sugar Balance Sheet

Sugar Year 2019-20	Sugar Year 2020-21	Details (In Million Tons)	Sugar Year 2021-22E
14.6	10.7	Opening stock as on 1st Oct	8.9
27.4	30.2	Production *	35.5
42.0	40.9	Total stocks	44.4
25.3	26.0	Consumption for the year	27.8
6.0	6.0	Exports - Subsidy based	-
-	-	Exports - Non - Subsidy based	9.9
10.7	8.9	Closing stock expected end September	6.7
4.0	-	Mandatory buffer stock	-
6.7	8.9	Net closing stock as on Sept 30th MMT	6.7
26%	34%	Closing stock as a % of consumption	24%
3.2	4.1	Closing stock as no. of months of consumption	3.2**
	2.0	* Post Diversion to Ethanol	4.0

0.8 2.0 * Post Diversion to Ethanol	4.0
-------------------------------------	-----

- GOI did not create buffer stock in SY20-21 & in SY 21-22, though sought by the industry
- Effective October 2021 export subsidy withdrawn as the international prices remain higher
- ** This is arrived based on average monthly release quota of 2.1 Million Tonne


Source: ISMA as of May'22







Sugar Strategy Devised







Sugar Strategies – Increase volume of Sugar | 1a. Asset Relocation

Haliyal crushing capacity increased


- Assets at Pudukkottai, Tamil Nadu, were transferred to Haliyal plant in Karnataka as there is surplus cane available & higher recovery in this region.
- With this, the capacity is enhanced from 7,500 TCD to 12,000 TCD
- Commercial production commenced in Q4 of FY'22; 1.45 LMT of Cane was crushed.

	Earlier TCD	Addition/Deletion	Current TCD
AP - Sankili	5,000	-	5,000
KN - Haliyal	7,500	4,500	12,000
KN - Bagalkot	6,000	-	6,000
KN - Ramdurg	5,000	-	5,000
TN - Nellikuppam	7,500	-	7,500
TN - Pugalur	4,800	-	4,800
TN – Pudukottai	4,500	(4,500)	-
TN - Pettavaithalai	3,500	(3,500)	Held for sale
Total	43,800	(3,500)	40,300
Operating	Closed		







Sugar Strategies - Increase volume of Sugar | 1b. Increase Cane volumes



Cane growth over FY'21

- ➤ TN 1.6 LMT
- ➤ AP 0.8 LMT
- ➤ KN 8.1 LMT
- \triangleright Overall expected to grow at a CAGR of 7%











Sugar Strategies – 2. Maximize realization from sugar



Retail share moving to 22%

- Growth from FY'19 to FY'22 : 183%
- Helped in better management of working capital







Sugar Strategies - 2. Maximize realization from sugar

Portfolio Buildup


- Pervasive Sweetener
- Next gen sweetener products
- To straddle price points
- To meet Consumers sweetener basket fully.


Distribution Growth

- Focus on South India
- Consolidate in Metro, Class1 and Class 2 towns
- Focus on Modern Trade and Selfservice store as phase 1 growth pillar
- Extend to B class outlets in FY'23
- Target 1 Lakh outlets by FY'25

Brand Building

- Implemented Master branding on packs
- Rigorous consumer research to understand need-state
- Focused communication build up on Brand equity
- Strengthening Digital initiatives
- Instore visibility prop up










Sugar Strategies – 2. Maximize realization from sugar


EID RETAIL PRODUCT SUITE








Sugar Strategies – 3. Maximize EBP Opportunity














Sugar Strategies – 4. Reduction in cash fixed cost

Reduction in Fixed Cost per MT is primarily on account of increased cane volumes












Sugar Segment Sales – Sugar, Distillery & Power









Total PBIT




PAT 101 163 2 865 284 286 286 284 286	E.I.D Parry (India) Limite	ed 5 Year Fina	ncials - Standalo	ne			
EBIDTA 274 205 235 1,271 478 PBIT 161 92 116 1,151* 358 PBT 48 (22) (20) 1,058 312 PAT 101 163 2 865 284 EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 Sugar 1,492 1,387 1,377 1,501 1,840 Internation [Rs.827 Cro-generation 77 72 83 90 101 Internation [Rs.827 Cro-generation 97 305 317 357 362 491 Cro-generation 1,874 1,776 1,817 1,953 2,432 Of Mutraceuticals 68 69 58 71 64 Total Revenue 1,942 1,845 1,875 2,024 2,496 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Untraceuticals 8 2 (8) 5 4 Unallocated (incl. exceptional) 150 185 1185 1185 1186 1160 232	EID Financial Performance	FY'18	FY'19	FY'20	FY'21	FY'22	INR in Cr
PBIT 161 92 116 1,151* 358 PBT 48 (22) (20) 1,058 312 PAT 101 163 2 865 284 EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 Sugar 1,492 1,387 1,377 1,501 1,840 Co-generation 77 72 83 90 101 Distillery 305 317 357 362 491 Sugar Segment 1,874 1,776 1,817 1,953 2,432 Nutraceuticals 68 69 58 71 64 Total Revenue 1,942 1,845 1,875 2,024 2,496 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4	Revenue from Operations	1,942	1,845	1,875	2,024	2,496	
PBT 48 (22) (20) 1,058 312 **FY'21 inclu PAT 101 163 2 865 284 **EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 **Co-generation 77 72 83 90 101 Distillery 305 317 357 362 491 Distillery 305 317 357 362 491 Sugar Segment 1,874 1,776 1,817 1,953 2,432 Nutraceuticals 68 69 58 71 64 FID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 **Sugar Segment 1,942 1,845 1,875 2,024 2,496 **EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 **Sugar Segment 1,942 1,845 1,875 2,024 2,496 **EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 **Sugar Segment 3,3 (95) 16 86 122 **Nutraceuticals 8 2 (8) 5 4 **Unallocated (incl. exceptional) 150 185 108 1066 2332	EBIDTA	274	205	235	1,271	478	
PAT 101 163 2 865 284 EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 Sugar 1,492 1,387 1,377 1,501 1,840 Co-generation 77 72 83 90 101 Sugar Segment 1,874 1,776 1,817 1,953 2,432 Nutraceuticals 68 69 58 71 64 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar Segment 1,942 1,845 1,875 2,024 2,496 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar Segment (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	PBIT	161	92	116	1,151*	358	Note:
EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 Sale of stake Coromands International Internationa	PBT	48	(22)	(20)	1,058	312	* FY'21 includes
EID Segment Revenue FY'18 FY'19 FY'20 FY'21 FY'22 Gugar 1,492 1,387 1,377 1,501 1,840 Internation [Rs.827 Crs.] Co-generation 77 72 83 90 101 - Increment dividend [Rs.827 Crs.] Siguar Segment 1,874 1,776 1,817 1,953 2,432 - Also loss of of long aim relocation. Four accuticals 68 69 58 71 64 of long aim relocation. Fotal Revenue 1,942 1,845 1,875 2,024 2,496 asset to Hampairm relocation. Gugar (29) (87) (8) 75 92 Gugar (29) (87) (8) 75 92 Gugar Segment 3 (95) 16 86 122 Sugar Segment 3 (95) 16 86 122 Sugar Segment 3 (95) 16 86 122 Sugar Segment 3 (95)	PAT	101	163	2	865	284	one-time profit sale of stake in
1,492 1,387 1,377 1,501 1,840	EID Segment Revenue	FY'18	FY'19	FY'20	FY'21	FY'22	Coromandel
Incremental Co-generation	Sugar	1,492	1,387	1,377	1,501	1,840	International
Sugar Segment 1,874 1,776 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,953 2,432 1,817 1,817 1,953 2,432 1,817 1,817 1,817 1,953 2,432 1,817 1,817 1,817 1,817 1,817 1,953 2,432 1,817 1,817 1,817 1,953 2,432 1,817 1,817 1,817 1,953 2,432 1,946 1,942 1,845 1,875 2,024 2,496 1,946 1,942 1,946 1,947 1,94	Co-generation	77	72	83	90	101	 Incremental
Sugar Segment 1,874 1,776 1,817 1,953 2,432 Nutraceuticals 68 69 58 71 64 Fotal Revenue 1,942 1,845 1,875 2,024 2,496 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	Distillery	305	317	357	362	491	dividend [Rs. 98
Nutraceuticals 68 69 58 71 64 Total Revenue 1,942 1,845 1,875 2,024 2,496 EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Unallocated (incl. exceptional) 150 185 108 1060 232	Sugar Segment	1,874	1,776	1,817	1,953	2,432	Also loss on acc
Fotal Revenue 1,942 1,845 1,875 2,024 2,496 asset to Ha 112 Crs] EID Segment Results FY'18 FY'19 FY'20 FY'21 FY'22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	Nutraceuticals	68	69	58	71	64	of Impairment a relocation cost
EID Segment Results FY 18 FY 19 FY 20 FY 21 FY 22 Sugar (29) (87) (8) 75 92 Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	Total Revenue	1,942	1,845	1,875	2,024	2,496	asset to Haliyal
Co-generation (5) (35) (37) (21) (13) Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	EID Segment Results	FY'18	FY'19	FY'20	FY'21	FY'22	112 Crs]
Distillery 37 27 61 32 43 Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	Gugar	(29)	(87)	(8)	75	92	
Sugar Segment 3 (95) 16 86 122 Nutraceuticals 8 2 (8) 5 4 Inallocated (incl. exceptional) 150 185 108 1060 232	Co-generation	(5)	(35)	(37)	(21)	(13)	
Nutraceuticals 8 2 (8) 5 4	Distillery	37	27	61	32	43	
Inallocated (incl. exceptional) 150 185 108 1060 232	Sugar Segment	3	(95)	16	86	122	
Jnallocated (incl. exceptional) 150 185 108 1060 232	Nutraceuticals	8	2	(8)	5	4	
	Jnallocated (incl. exceptional)	150	185	108	1060	232	23





Sugar segment PBIT FY'21 vs FY'22









Debt Position - Standalone

Moving towards **0-Debt**



Long term loan to fund Ethanol projects

Debt reduction initiative helping in reducing Finance Cost



Rating from Agencies					
Long-term facilities CRISIL 'AA-' Positive outlook					
Short-term facilities	CRISIL 'A1+' CARE 'A1+'				




CONSOLIDATED NUTRACEUTICALS PERFORMANCE





Nutraceuticals Product Mix









INR in Cr

Particulars	FY'18	FY'19	FY'20	FY'21	FY'22
Greens	30	27	30	44	69
Joint Health	111	117	83	96	80
Prostate Health	75	67	97	115	128
Total	216	210	210	254	277



Nutraceuticals Initiatives



Saw Palmetto growth

8% growth in FY'22 in the core saw palmetto B2B vertical (Sales -\$16.3 Mn)



Significant Market share gain - Spirulina

- US. Growth in FY'22 from 170 MT to 270 MT
- Market development of Greens through acquisition of New customers



Flomentum - B2C


- Built science equity for the efficacy of saw palmetto on Prostate Health.
- Initiated field force deployment for developing the recommendation from Urologists.









Consolidated Nutraceuticals - 5 Years' Financial performance









Sugar Refinery

Sweeter up the value chain

Adding value & volume to manage restricted spread environments, increase profitability and create premium customer segments



Parry Sugar Refinery India Private Limited - Sugar Scenario

Global Demand Supply moving to surplus

 Record production in India will compensate for lower output in Brazil & Europe

Indian Exports to continue

With expectation of a higher crop in SY 22-23, India will continue to export sugar (although lower than SY 21-22). Opportunity for port- based refineries to source Indian sugar.

Robust Refined sugar demand

Is expected to continue, export ban in some countries keeping supply tight.

White Premium to remain elevated

due to refined sugar demand and refining cost increases due to surging energy prices







Refinery Performance - Standalone

Operational Performance	UOM	FY'18	FY'19	FY'20	FY'21	FY'22
Capacity	LMT	8.00	8.00	9.00	9.00	9.00
Melting Rate	MT/Day	2,155	2,445	2,700	2,564	2,595
Production	LMT	6.61	6.99	6.37	7.90	6.11
Break Bulk	%	86	85	84	87	94
Container	%	14	15	16	13	6
Sales	LMT	6.71	5.36	7.59	8.21	6.23
Revenue from Operations	USD Mn	375	205	283	303	269
EBITDA	USD Mn	(0.6)	0.3	10	(8.9)	9.2
EBIT	USD Mn	(4.9)	(4.2)	5.3	(13.5)	4.7
РВТ	USD Mn	(11.8)	(12.7)	(2.7)	(18.7)	(1.8)
Capital Employed	USD Mn	93.2	196.7	152.1	55.3	75.2
External Borrowing	USD Mn	89.4	189.7	156.9	27.7	85.4
ROCE	%	(5.3)%	(2.9)%	3%	(13.1)%	7.05%



CONSOLIDATED DEBT & CAPITAL EMPLOYED





Consolidated External Borrowings Segment wise

					INR in Cr
Segment	FY'18	FY'19	FY'20	FY'21	FY'22
Sugar	128	157	287	486	104
Refinery	717	1,311	1,187	203	647
Nutra	23	46	68	68	70
Others	873	655	731	39	-
Total	1,741	2,169	2,273	796	821

Note:

- Sugar Long term loans to fund Ethanol Projects
- Refinery & Nutra Funding for Working capital





Consolidated Capital Employed & ROCE Segment wise

	UOM	Sugar	Nutra	Refinery	Others	Total
Capital Employed	INR in Cr	1,425	293	511	447	2,676
PBIT	INR in Cr	117	(8)	36	211	356
ROCE	%	8.21%	(2.73)%	7.05%	47.20%	13.30%





- Relocated plants to increase the capacity utilization

Reduced debt. Currently only working capital debt

- Significant investment in increasing distillery capacity
- Higher retail mix with clearly laid out growth path
- Capability to pass through dividend
- Cost efficient refinery operation
- Working on Nutraceuticals growth strategy



Thank You....





Glossary

	ACRONYMS						
AP	Andhra Pradesh	Mn	Million				
Cr	Crore	MSP	Minimum Selling Price				
EBIT	Earnings Before Interest & Tax	MT	Metric Tonne				
EBITDA	Earnings Before Interest, Tax & Depreciation	MW	Mega Watt				
EBP	Ethanol Blending Program	PAT	Profit After Tax				
FRP	Fair & Remunerative Price	PBIT	Profit Before Interest & Tax				
FY	Financial Year	PBT	Profit Before Tax				
GOI	Government of India	PPRS	Parry's Pure Refined Sugar				
INR	Indian Rupee	ROCE	Return on Capital Employed				
Kg	Kilogram	SCM	Supply Chain Management				
KLPD	Kilo Litre Per Day	SY	Sugar Year				
KN	Karnataka	TCD	Tonne Crushed Per Day				
LL	Lakh Litre	TN	Tamil Nadu				
LMT	Lakh Metric Tonne	USD	United States Dollar				
Ltr	Litre	USP	United States Pharmacopoeia				
LU	Lakh Unit	W&C	White & Clean				
MMT	Million Metric Tonne	WL	White Label				